AstraZeneca “buried” unfavorable studies about its antipsychotic drug Seroquel, according to an internal e-mail unsealed as part of litigation over the medicine.
The drugmaker failed to publicize results of at least three clinical trials of Seroquel and engaged in “cherry picking” of data from one of those studies for use in a presentation, an AstraZeneca official said in a December 1999 e-mail unsealed today under an agreement between the company and lawyers for patients. The company faces about 9,000 lawsuits claiming the drugmaker failed to properly warn users that Seroquel can cause diabetes and other health problems.
“The larger issue is how we face the outside world when they begin to criticize us for suppressing data,” John Tumas, an AstraZeneca publications manager, told colleagues in the e-mail.
No comments:
Post a Comment